Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab plus methotrexate tapering versus stable methotrexate in severe active rheumatoid arthritis
2011-005260-20Phase 4Terminated
- Sponsor
- Roche
- Start
- May 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tocilizumab and methotrexate in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: Maintenance of EULAR response from week 24 to week 56. Started May 2012; status: terminated.
02
Drugs
tocilizumabmethotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-005260-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005260-20.